501684-22-6

Upstream product

• 179688-14-3 methyl 3,4-bis{[2-(methyloxy)ethyl]oxy}benzoate 
• 80407-64-3 3,4-bis(2-methoxyethoxy)benzaldehyde 
• 139-85-5 3,4-dihydroxybenzaldehyde 
• 121-33-5 vanillin 
• 819813-71-3 3,4-bis(2-methoxyethoxy)-benzoic acid 
• 3943-89-3 Ethyl protocatechuate 
• 2150-43-8 3,4-dihydroxybenzoic acid methyl ester 
• 99-50-3 3,4-Dihydroxybenzoic acid 

Downstream Products

• 179688-29-0 6,7-bis(2-methoxyethoxy)-3,4-dihydroquinazolin-4-one 
• 1001416-73-4 4,5-bis (2-methoxyethoxy)-2-nitrobenzoic acid 
• 476168-17-9 2-amino-4,5-bis-(2-methoxyethoxy)-benzoic acid methyl ester 
• 183322-18-1 4-chloro-6,7-bis(2-methoxyethoxy)quinazoline 
• 882511-68-4 [6,7-bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-[3-(3-dicyclohexylamino-prop-1-ynyl)-phenyl]-amine 
• 882511-69-5 [6,7-bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-[4-(3-dicyclohexylamino-prop-1-ynyl)-phenyl]-amine 
• 882511-70-8 (3-{3-[6,7-bis-(2-methoxy-ethoxy)-quinazolin-4-yloxy]-phenyl}-prop-2-ynyl)-dicyclohexyl-amine 
• 882511-71-9 (3-{4-[6,7-bis-(2-methoxy-ethoxy)-quinazolin-4-yloxy]-phenyl}-prop-2-ynyl)-dicyclohexyl-amine 
• 882511-65-1 [6,7-bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(4-iodo-phenyl)-amine 
• 882511-64-0 [6,7-bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-iodo-phenyl)-amine 
• 882511-66-2 4-(3-iodo-phenoxy)-6,7-bis-(2-methoxy-ethoxy)-quinazoline 
• 882511-67-3 4-(4-iodo-phenoxy)-6,7-bis-(2-methoxy-ethoxy)-quinazoline 
• 179688-29-0 6,7-bis-(2-methoxyethoxy)-4(3H)quinazolinone 

Relevant academic research and scientific papers

Preparation method of erlotinib intermediate

The invention relates to a preparation method of an erlotinib intermediate. The method concretely comprises the following steps: 1, dissolving vanillin in an organic solvent I, adding aluminum trichloride, adding pyridine in a dropwise manner, and reacting to obtain ELTA; 2, dissolving the ELTA in an organic solvent II, adding 2-chloroethylmethyl ether, potassium carbonate and a phase transfer catalyst, and reacting to obtain ELTB; 3, adding the ELTB to water, adding an alkali and potassium permanganate, and reacting to obtain ELTC; 4, adding concentrated sulfuric acid to methanol in a dropwise manner, adding the ELTC to the above reaction system, and reacting to obtain ELTD; 5, adding concentrated sulfuric acid to concentrated nitric acid in a dropwise manner, dissolving the ELTD in an organic solvent IV, adding a prepared mixed acid to the reaction system, and reacting to obtain ELTE; 6, adding the ELTE, iron powder and ammonium chloride to an organic solvent V, adding concentrated hydrochloric acid in a dropwise manner, and reacting to obtain ELTF; and 7, adding the ELTF, trimethyl orthoformate and ammonium acetate to an organic solvent VI, and reacting to obtain the erlotinib intermediate.

Design, synthesis of novel quinazolone alkaloids derivatives as potential antitumor agents

Several novel quinazolone alkaloids derivatives were synthesized. Some of the target compounds were determined against human prostate cancer DU145 and pancreatic cancer Miacapa2 cells in vitro. The entire compounds had been identified by 1HNMR, 13CNMR, IR, MS and EA.

Method of Synthesizing 6,7-Substituted 4-Anilino Quinazoline

A method of synthesizing 6,7-substituted 4-anilino quinazoline employs 3,4-substituted benzoic acid as an initial reactant, and the 6,7-substituted 4-anilino quinazoline is obtained by an esterifying step, a nitrating step, a reducing step, a cyclizing step, and an one-pot reaction. In the above method, the initial reactant has low cost and yield. of the 6,7-substituted 4-anilino quinazoline is high, therefore, production cost can be reduced effectively, and competitive power of the product of the 6,7-substituted 4-anilino quinazoline can be improved.

Synthesis and biological evaluation of allenic quinazolines using palladium-catalyzed hydride-transfer reaction

Allenic quinazolines 13a-h were designed as mimics of Tarceva, which is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, and synthesized from the corresponding 4-(iodoanilino)quinazolines or 4-(iodophenoxy)quinazolines with N,N-dicyclohexylprop-2-ynylamine by the Sonogashira coupling followed by palladium-catalyzed hydride-transfer reaction. Cell growth inhibition of 13a-h toward A431, Kato III, SKBR3, and HepG2 was examined. Among the compounds synthesized, 13a showed a similar cell growth inhibition to Tarceva. Moreover, 13d and 13h exhibited a specific growth inhibition toward Kato III cells (IC50 = 12 and 4.7 μM, respectively), although a significant inhibition toward other three cell lines was not observed at a 100 μM concentration of compounds.

Syntheses and EGFR and HER-2 kinase inhibitory activities of 4-anilinoquinoline-3-carbonitriles: Analogues of three important 4-anilinoquinazolines currently undergoing clinical evaluation as therapeutic antitumor agents

The syntheses and biological evaluations of 4-anilinoquinoline-3-carbonitrile analogues of the three clinical lead 4-anilinoquinazolines Iressa, Tarceva, and CI-1033 are described. The EGFR and HER-2 kinase inhibitory activities and the cell growth inhibition of the two series are compared with each other and with the clinical lead EKB-569. Similar activities are observed between these two series.